News Article

As the U.S. introduces sweeping tariff reforms and redefines global trade dynamics, Aldous Mitchell, Partner at Candesic, highlights how these shifts are reshaping strategies for life sciences firms across the U.S. and Europe in the May edition of LaingBuisson’s HealthcareMarkets.

The U.S. remains a vital market for European life sciences, investors, and innovators. While the UK was the first to sign a trade deal with the U.S. (after the time of writing), trade terms on pharmaceuticals have not yet been agreed, though there is an expectation of achieving favourable treatment.